Orbimed Genesis
ActiveFiled to raiseNew York, NYBiotechnology, Pharmaceuticals, HealthcareLast fund filed September 2025
5 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| OrbiMed Private Investments X | September 2025 | $1.8B | $1.7B | 119 |
| OrbiMed Asia Partners VI | September 2025 | $850M | $534M | 45 |
| OrbiMed RCO V Offshore Feeder | November 2024 | $1.8B | $1.2B | 31 |
| OrbiMed Royalty & Credit Opportunities V | November 2024 | $1.8B | $1.2B | 52 |
| OrbiMed RCO IV Offshore Feeder | July 2022 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
20 partners are named across this firm’s filings, 5 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David BonitaNot on the current fund | Selective | Biotech & pharma, Medical devices | 15 |
Classified sectors of Orbimed Genesis’s own portfolio companies, based on 106 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Orbimed Asia Partners | 110 | 9 METERS BIOPHARMA, ACCELERON PHARMA, ACM Research, Acutus Medical, Adaptimmune, ADARx Pharmaceuticals, Adela, Adicet Bio, Aeonsemi, Alector, Alpfa Medical, Alpine Immune Sciences, ALPINE IMMUNE SCIENCES, Alterome Therapeutics, Aragon Pharmaceuticals, Arcutis Biotherapeutics, ArriVent Biopharma, Arsanis, Ascendis Pharma A/S, Atox Bio, Audentes Therapeutics, AVEDRO, Avenzo Therapeutics, Beet, Belenos Biosciences, BioIntelliSense, BioVaxys Technology, BlossomHill Therapeutics, Capstan Therapeutics, CB THERAPEUTICS, CERAPEDICS, Chemomab Therapeutics, Cleave Biosciences, Clementia Pharmaceuticals, Compass Therapeutics, Compass Therapeutics, Corvus Pharmaceuticals, CranioVation, Decibel Therapeutics, DOCUSMART, E-SCAPE BIO, Edgewise Therapeutics, EdjSports, EQDerivatives, Everfit Technologies, Evozyne, FORE US Bio, Galecto, Garuda Therapeutics, Gemini Therapeutics, Gennao Bio, IGENICA, Ikena Oncology, IMARA, ImmPACT Bio USA, Intellia Therapeutics, Intrinsic Technologies, Keros Therapeutics, Kinnate Biopharma, KONOST, Kumquat Biosciences, LogicBio Therapeutics, Lomond Therapeutics Holdings, Loxo Oncology, MBX Biosciences, Medigus, MID Labs, NetSapiens, NeuroPace, Notitia Biotechnologies, Novus Therapeutics, Odyssey Therapeutics, PFARADIGM Health, PMV Pharmaceuticals, Prelude Therapeutics, Prevail Therapeutics, Principia Biopharma, ProNAi Therapeutics, RECODE THERAPEUTICS, Revnue, RHYTHM PHARMACEUTICALS, Roka BioScience, RVA Entertainment Holdings, scPharmaceuticals, Scribe Therapeutics, SELECTA BIOSCIENCES, SI-BONE, Silverback Therapeutics, Singulex, Sparrow Pharmaceuticals, Speed System Golf, Springbox Labs, SpringWorks Therapeutics, SpringWorks Therapeutics, Star Therapeutics, StudentRoomStay International, Synthorx, Technosys Digital Health Solutions, Terremoto Biosciences, Theseus Pharmaceuticals, Thrombolex, TP Therapeutics, Treeline Biosciences, Tricida, TROPICAL RACING, VANQUA BIO, VIEWRAY, ViewRay, Watershed Informatics, Xtant Medical Holdings |
| $500M |
| $344M |
| 18 |
| OrbiMed Asia Partners V | April 2022 | $1.1B | $652M | 68 |
| OrbiMed Royalty & Credit Opportunities IV | April 2022 | $1.8B | $1.2B | 113 |
| OrbiMed Private Investments IX | April 2022 | $1.9B | $1.8B | 141 |
| OrbiMed Genesis Fund | April 2020 | Indefinite | $146M | 20 |
| OrbiMed New Horizons Fund | April 2020 | Indefinite | $62M | 55 |
| OrbiMed Asia Partners IV | March 2020 | $750M | $487M | 86 |
| OrbiMed Private Investments VIIIFiled to raise in 2020, with no closing reported yet. | 2020 | $1.4B | $0 | 0 |
| OrbiMed Genesis Fund | November 2019 | Indefinite | $353M | 107 |
| OrbiMed Royalty & Credit Opportunities III | 2019 | $1.2B | $890M | 69 |
| OrbiMed Private Investments VIIFiled to raise in 2018, with no closing reported yet. | 2018 | $1B | $0 | 0 |
| OrbiMed Asia Partners III | March 2017 | $540M | $540M | 97 |
| OrbiMed Israel Partners IIFiled to raise in 2015, with no closing reported yet. | 2015 | $300M | $0 | 0 |
| OrbiMed Royalty Opportunities II | 2015 | $900M | $900M | 83 |
| OrbiMed Private Investments VIFiled to raise in 2015, with no closing reported yet. | 2015 | $950M | $0 | 0 |
| OrbiMed Global Healthcare Fund | July 2014 | Indefinite | $113M | 10 |
| OrbiMed Global Healthcare Associates Fund | February 2014 | Indefinite | $17M | 7 |
| OrbiMed Global Healthcare Fund | October 2013 | Indefinite | $988M | 11 |
| OrbiMed Partners II | June 1998 | Indefinite | $1.8B | 880 |
| OrbiMed Partners | December 1996 | Indefinite | $2.6B | 779 |
| OrbiMed Partners | 1993 | Indefinite | $128M | 130 |
| 3 |
| Carl Gordon | Selective | Biotech & pharma, Healthcare services | 32 | 2 |
| Jonathan SilversteinNot on the current fund | Slowing | Biotech & pharma, Medical devices, Digital health | 13 | 1 |
| Peter ThompsonNot on the current fund | Slowing | Biotech & pharma, Fintech, Gaming & entertainment | 21 | 1 |
| Anat NaschitzNot on the current fund | Quiet | None listed | 1 | 0 |
| Brian BurkholderNot on the current fund | Quiet | None listed | 0 | 0 |
| C. StevensNot on the current fund | Quiet | None listed | 0 | 0 |
| David Wang | Quiet | Biotech & pharma, Manufacturing & industrials, Robotics & hardware | 13 | 0 |
| Erez ChimovitsNot on the current fund | Quiet | Biotech & pharma | 9 | 0 |
| Geoffrey HsuNot on the current fund | Quiet | None listed | 0 | 0 |
| Graham CollisNot on the current fund | Quiet | None listed | 0 | 0 |
| Jonathan WangNot on the current fund | Quiet | Biotech & pharma, Enterprise software, Robotics & hardware | 5 | 0 |
| Matthew RizzoNot on the current fund | Quiet | Biotech & pharma, Medical devices | 2 | 0 |
| Michael ShefferyNot on the current fund | Quiet | None listed | 0 | 0 |
| Mona AshiyaNot on the current fund | Quiet | Biotech & pharma | 2 | 0 |
| Nissim DarvishNot on the current fund | Quiet | Biotech & pharma | 3 | 0 |
| Samuel IsalyNot on the current fund | Quiet | None listed | 0 | 0 |
| Sunny Sharma | Quiet | Enterprise software, Gaming & entertainment | 2 | 0 |
| Sven Borho | Quiet | None listed | 0 | 0 |
| W. Neild | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Orbimed Genesis’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Caduceus Capital | 44 | ACCELERON PHARMA, ADARx Pharmaceuticals, Adicet Bio, Alector, Alterome Therapeutics, Aragon Pharmaceuticals, Arcutis Biotherapeutics, ArriVent Biopharma, Arsanis, Ascendis Pharma A/S, Audentes Therapeutics, AVEDRO, Avenzo Therapeutics, Belenos Biosciences, BlossomHill Therapeutics, CERAPEDICS, Compass Therapeutics, Compass Therapeutics, Garuda Therapeutics, Gemini Therapeutics, IGENICA, Intellia Therapeutics, Keros Therapeutics, Kinnate Biopharma, Kumquat Biosciences, Lomond Therapeutics Holdings, MBX Biosciences, NeuroPace, Odyssey Therapeutics, Prevail Therapeutics, RHYTHM PHARMACEUTICALS, Roka BioScience, scPharmaceuticals, Scribe Therapeutics, SELECTA BIOSCIENCES, Singulex, Springbox Labs, SpringWorks Therapeutics, SpringWorks Therapeutics, Star Therapeutics, Technosys Digital Health Solutions, Theseus Pharmaceuticals, TP Therapeutics, VANQUA BIO |
| 270 Healthcare Growth | 8 | Audentes Therapeutics, Chemomab Therapeutics, Compass Therapeutics, Compass Therapeutics, Gennao Bio, SpringWorks Therapeutics, SpringWorks Therapeutics, VANQUA BIO |
| Vivo Innovation | 6 | ADARx Pharmaceuticals, Ascendis Pharma A/S, AVEDRO, BlossomHill Therapeutics, ProNAi Therapeutics, TP Therapeutics |
| Bain Capital Life Sciences | 4 | ADARx Pharmaceuticals, Arcutis Biotherapeutics, SpringWorks Therapeutics, SpringWorks Therapeutics |
| Sofinnova Venture Partners | 4 | ArriVent Biopharma, Ascendis Pharma A/S, AVEDRO, Star Therapeutics |
| U.S Venture Partners | 4 | Cleave Biosciences, Edgewise Therapeutics, Silverback Therapeutics, Sparrow Pharmaceuticals |
| Vida Ventures | 4 | Alterome Therapeutics, Capstan Therapeutics, RECODE THERAPEUTICS, Roka BioScience |
| Atlas Venture | 3 | Gemini Therapeutics, Ikena Oncology, Intellia Therapeutics |
| Borealis | 3 | AVEDRO, Compass Therapeutics, Compass Therapeutics |
| NEA | 3 | Adaptimmune, IMARA, MBX Biosciences |
| Polaris Partners | 3 | ACCELERON PHARMA, Arsanis, SELECTA BIOSCIENCES |
| Seaview Capital Partners | 3 | Avenzo Therapeutics, Kinnate Biopharma, Theseus Pharmaceuticals |
| 82vs | 2 | Arsanis, Compass Therapeutics |
| Abingworth Bioventures | 2 | AVEDRO, Odyssey Therapeutics |
A shared board seat: a company where filings name a Orbimed Genesis partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.